China Declares Outbreak Past Peak, But Drug Makers Far From Recovery
Good Old Days May Never Return?
Executive Summary
Clinical studies in hiatus, marketing on hold, demand directionless and supply disrupted. Pharma firms in China say it’s likely the good old days may never come back.
You may also be interested in...
Volume-Based Purchasing Looms Larger In Post-Coronavirus China
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Coronavirus Update: Trump Spreads Confusion On Drug Treatments, Biogen Fires China Flight Employee
Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.